Clinical Trials

21 enrolled 11 charts

CNSLymphoid

Lymphoma, Non-Hodgkin, Neuroblastoma, Central Nervous System Neoplasms

NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

647 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT01256359 2024-08-15

DOC-MEK

83 enrolled 60 charts

Melanoma

NCT02393690 2024-07-26

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

60 enrolled 12 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02337530 2024-03-21

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

62 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT03745989 2023-07-27

MK-8353-014

30 enrolled 19 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

334 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01586624 2021-10-07

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

61 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00551070 2020-12-03

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

52 enrolled 11 charts

Cystadenocarcinoma, Serous

NCT01222689 2020-07-31

Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

46 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01021748 2018-08-07

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

63 enrolled 17 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT00890825 2018-06-20

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

88 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

120 enrolled 8 charts

Uveal Melanoma

NCT01229150 2017-05-23

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

89 enrolled 28 charts

Phase EARLY_PHASE1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00970359 2017-04-12

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Phase NA Completed

24 enrolled 8 charts

Head & Neck

Neoplasm Metastasis, Thyroid Diseases, Thyroid Neoplasms

NCT01313039 2017-02-07

Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer

4 enrolled 5 charts

Breast

Breast Neoplasms

NCT00559949 2017-01-30

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

39 enrolled 8 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT01605916 2016-10-21

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

33 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02322749 2016-08-31

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

48 enrolled 16 charts

Tumor-Agnostic

Neoplasms

NCT02063230 2016-07-21

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

32 enrolled 12 charts

Other solid neoplasm

Solid Tumors

NCT00553332 2016-04-22

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

29 enrolled 11 charts

Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular

NCT02238782 2016-04-05

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

21 enrolled 4 charts

Tumor-Agnostic

Neoplasms

NCT00936221 2016-03-14

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

385 enrolled 11 charts

Melanoma

NCT00888134 2016-01-15

Selumetinib in Cancers With BRAF Mutations

28 enrolled 9 charts

Adult Solid Neoplasm

NCT02056392 2015-11-09

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

54 enrolled 31 charts

Other solid neoplasm

Solid Tumours

NCT01206140 2015-10-05

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

70 enrolled 8 charts

Sarcoma

NCT01085214 2015-08-19

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

37 enrolled 9 charts

Plasma cell

Multiple Myeloma

NCT00866177 2015-08-11

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

167 enrolled 6 charts

Melanoma

NCT00604721 2014-05-28

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer